Literature DB >> 23403630

Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis.

Inga Hinrichsen1, Angela Brieger, Jörg Trojan, Stefan Zeuzem, Mef Nilbert, Guido Plotz.   

Abstract

PURPOSE: Lynch syndrome is caused by a germline mutation in a mismatch repair gene, most commonly the MLH1 gene. However, one third of the identified alterations are missense variants with unclear clinical significance. The functionality of these variants can be tested in the laboratory, but the results cannot be used for clinical diagnosis. We therefore aimed to establish a laboratory test that can be applied clinically. EXPERIMENTAL
DESIGN: We assessed the expression, stability, and mismatch repair activity of 38 MLH1 missense variants and determined the pathogenicity status of recurrent variants using clinical data.
RESULTS: Four recurrent variants were classified as neutral (K618A, H718Y, E578G, V716M) and three as pathogenic (A681T, L622H, P654L). All seven variants were proficient in mismatch repair but showed defects in expression. Quantitative PCR, pulse-chase, and thermal stability experiments confirmed decreases in protein stability, which were stronger in the pathogenic variants. The minimal cellular MLH1 concentration for mismatch repair was determined, which corroborated that strongly destabilized variants can cause repair deficiency. Loss of MLH1 tumor immunostaining is consistently reported in carriers of the pathogenic variants, showing the impact of this protein instability on these tumors.
CONCLUSIONS: Expression defects are frequent among MLH1 missense variants, but only severe defects cause Lynch syndrome. The data obtained here enabled us to establish a threshold for distinguishing tolerable (clinically neutral) from pathogenic expression defects. This threshold allows the translation of laboratory results for uncertain MLH1 variants into pathogenicity statements for diagnosis, thereby improving the targeting of cancer prevention measures in affected families. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403630     DOI: 10.1158/1078-0432.CCR-12-3299

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  12 in total

1.  Full-length transcript amplification and sequencing as universal method to test mRNA integrity and biallelic expression in mismatch repair genes.

Authors:  Monika Morak; Kerstin Schaefer; Verena Steinke-Lange; Udo Koehler; Susanne Keinath; Trisari Massdorf; Brigitte Mauracher; Nils Rahner; Jessica Bailey; Christiane Kling; Tanja Haeusser; Andreas Laner; Elke Holinski-Feder
Journal:  Eur J Hum Genet       Date:  2019-07-22       Impact factor: 4.246

2.  Classifying MMR variants: time for revised nomenclature in Lynch syndrome.

Authors:  Y Nancy You; Eduardo Vilar
Journal:  Clin Cancer Res       Date:  2013-03-26       Impact factor: 12.531

3.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

4.  Consequences of germline variation disrupting the constitutional translational initiation codon start sites of MLH1 and BRCA2: Use of potential alternative start sites and implications for predicting variant pathogenicity.

Authors:  Michael T Parsons; Phillip J Whiley; Jonathan Beesley; Mark Drost; Niels de Wind; Bryony A Thompson; Louise Marquart; John L Hopper; Mark A Jenkins; Melissa A Brown; Kathy Tucker; Linda Warwick; Daniel D Buchanan; Amanda B Spurdle
Journal:  Mol Carcinog       Date:  2013-12-02       Impact factor: 4.784

5.  Clinical and Molecular Characterization of Brazilian Patients Suspected to Have Lynch Syndrome.

Authors:  Felipe Carneiro da Silva; José Roberto de Oliveira Ferreira; Giovana Tardin Torrezan; Márcia Cristina Pena Figueiredo; Érika Maria Monteiro Santos; Wilson Toshihiko Nakagawa; Rafael Canfield Brianese; Ligia Petrolini de Oliveira; Maria Dirlei Begnani; Samuel Aguiar-Junior; Benedito Mauro Rossi; Fábio de Oliveira Ferreira; Dirce Maria Carraro
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

6.  Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Authors:  Keith Nykamp; Michael Anderson; Martin Powers; John Garcia; Blanca Herrera; Yuan-Yuan Ho; Yuya Kobayashi; Nila Patil; Janita Thusberg; Marjorie Westbrook; Scott Topper
Journal:  Genet Med       Date:  2017-05-11       Impact factor: 8.822

7.  A functional assay-based procedure to classify mismatch repair gene variants in Lynch syndrome.

Authors:  Mark Drost; Yvonne Tiersma; Bryony A Thompson; Jane H Frederiksen; Guido Keijzers; Dylan Glubb; Scott Kathe; Jan Osinga; Helga Westers; Lisa Pappas; Kenneth M Boucher; Siska Molenkamp; José B Zonneveld; Christi J van Asperen; David E Goldgar; Susan S Wallace; Rolf H Sijmons; Amanda B Spurdle; Lene J Rasmussen; Marc S Greenblatt; Niels de Wind; Sean V Tavtigian
Journal:  Genet Med       Date:  2018-12-03       Impact factor: 8.822

8.  Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database.

Authors:  Bryony A Thompson; Amanda B Spurdle; John-Paul Plazzer; Marc S Greenblatt; Kiwamu Akagi; Fahd Al-Mulla; Bharati Bapat; Inge Bernstein; Gabriel Capellá; Johan T den Dunnen; Desiree du Sart; Aurelie Fabre; Michael P Farrell; Susan M Farrington; Ian M Frayling; Thierry Frebourg; David E Goldgar; Christopher D Heinen; Elke Holinski-Feder; Maija Kohonen-Corish; Kristina Lagerstedt Robinson; Suet Yi Leung; Alexandra Martins; Pal Moller; Monika Morak; Minna Nystrom; Paivi Peltomaki; Marta Pineda; Ming Qi; Rajkumar Ramesar; Lene Juel Rasmussen; Brigitte Royer-Pokora; Rodney J Scott; Rolf Sijmons; Sean V Tavtigian; Carli M Tops; Thomas Weber; Juul Wijnen; Michael O Woods; Finlay Macrae; Maurizio Genuardi
Journal:  Nat Genet       Date:  2013-12-22       Impact factor: 38.330

9.  The MLH1 c.1852_1853delinsGC (p.K618A) variant in colorectal cancer: genetic association study in 18,723 individuals.

Authors:  Anna Abulí; Luis Bujanda; Jenifer Muñoz; Stephan Buch; Clemens Schafmayer; Maria Valeria Maiorana; Silvia Veneroni; Tom van Wezel; Tao Liu; Helga Westers; Clara Esteban-Jurado; Teresa Ocaña; Josep M Piqué; Montserrat Andreu; Rodrigo Jover; Angel Carracedo; Rosa M Xicola; Xavier Llor; Antoni Castells; Malcolm Dunlop; Robert Hofstra; Annika Lindblom; Juul Wijnen; Paolo Peterlongo; Jochen Hampe; Clara Ruiz-Ponte; Sergi Castellví-Bel
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240

10.  Lynch syndrome associated with two MLH1 promoter variants and allelic imbalance of MLH1 expression.

Authors:  Luke B Hesson; Deborah Packham; Chau-To Kwok; Andrea C Nunez; Benedict Ng; Christa Schmidt; Michael Fields; Jason W H Wong; Mathew A Sloane; Robyn L Ward
Journal:  Hum Mutat       Date:  2015-04-17       Impact factor: 4.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.